866-997-4948(US-Canada Toll Free)

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 73 Pages

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H2 2017

Summary

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H2 2017, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Respiratory, Central Nervous System, Immunology, Musculoskeletal Disorders and Ophthalmology which include indications Solid Tumor, Lymphangioleiomyomatosis, Non-Small Cell Lung Cancer, Ulcerative Colitis, Alcohol Addiction, Alzheimer's Disease, Bladder Cancer, Breast Cancer, Cancer Pain, Cervical Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Hepatocellular Carcinoma, Inflammatory Bowel Disease, Interstitial Lung Fibrosis, Keratoconjunctivitis sicca (Dry Eye), Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Peritoneal Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer and Systemic Sclerosis (Scleroderma).

Furthermore, this report also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview 7
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 13
Products under Development by Universities/Institutes 17
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment 19
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development 24
AbbVie Inc 24
Asana BioSciences LLC 24
AstraZeneca Plc 24
Boehringer Ingelheim GmbH 25
Lead Discovery Center GmbH 26
Onconova Therapeutics Inc 27
TopiVert Ltd 27
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles 28
AD-80 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ASN-006 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
ilorasertib - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
JRP-890 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
nintedanib - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ON-150030 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
saracatinib difumarate - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecules to Inhibit SRC for Oncology - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
TOP-1210 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
TOP-1288 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
TOP-1630 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
TOP-1890 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
TPX-0005 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products 57
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products 59
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones 60
Featured News & Press Releases 60
Nov 10, 2017: Results from six-month lung imaging study showed slowing of fibrotic progression in patients with IPF treated with Ofev versus placebo 60
Oct 23, 2017: Ofev demonstrates consistent long-term efficacy in IPF regardless of baseline lung function 60
Sep 11, 2017: Safety and efficacy results from the INJOURNEYTM trial investigating OFEV (nintedanib) with add-on pirfenidone provide new data to support nintedanibs key role in IPF 62
Jul 19, 2017: Onyx helps accelerate TopiVert's compound to clinic 63
Jul 19, 2017: TopiVert Provides Update on TOP1630 64
Jun 27, 2017: TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic Rearrangements 64
Jun 05, 2017: Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO 2017 65
May 24, 2017: IPF patients treated with OFEV (nintedanib) versus placebo were twice as likely to have improved or stable lung function 66
Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data on ON dual FLT3 and Src inhibitor 150030 at 2017 American Association of Cancer Research Annual Meeting 67
Mar 20, 2017: Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases 67
Dec 14, 2016: Nintedanib granted orphan drug designation for treatment of mesothelioma 68
Dec 07, 2016: Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer 68
Nov 28, 2016: TopiVert Receives IND Approval for TOP1630 in the Treatment of Dry Eye Syndrome 69
Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 69
Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 10
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16
Number of Products under Investigation by Universities/Institutes, H2 2017 17
Products under Investigation by Universities/Institutes, H2 2017 18
Number of Products by Stage and Mechanism of Actions, H2 2017 19
Number of Products by Stage and Mechanism of Actions, H2 2017 (Contd..1), H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 22
Number of Products by Stage and Molecule Type, H2 2017 23
Pipeline by AbbVie Inc, H2 2017 24
Pipeline by Asana BioSciences LLC, H2 2017 24
Pipeline by AstraZeneca Plc, H2 2017 25
Pipeline by Boehringer Ingelheim GmbH, H2 2017 26
Pipeline by Lead Discovery Center GmbH, H2 2017 27
Pipeline by Onconova Therapeutics Inc, H2 2017 27
Pipeline by TopiVert Ltd, H2 2017 27
Dormant Products, H2 2017 57
Dormant Products, H2 2017 (Contd..1), H2 2017 58
Discontinued Products, H2 2017 59

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 19
Number of Products by Routes of Administration, H2 2017 21
Number of Products by Stage and Routes of Administration, H2 2017 21
Number of Products by Stage and Molecule Type, H2 2017 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *